Zilver® PTX® V Clinical Study

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 18, 2016

Study Completion Date

February 15, 2021

Conditions
Peripheral Arterial Disease
Interventions
DEVICE

Zilver® PTX® Drug-Eluting Peripheral Stent

Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.

Trial Locations (17)

10032

Columbia University Medical Center, New York

10065

New York-Presbyterian/ Weill Cornell Medical Center, New York

17011

Holy Spirit Hospital, Camp Hill

20010

Washington Hospital Center, Washington D.C.

21224

Bayview Medical Center, Baltimore

29204

South Carolina Heart Center, Columbia

29615

Greenville Hospital System, Greenville

32216

First Coast Cardiovascular Institute, Jacksonville

32605

The Cardiac and Vascular Institute, Gainesville

32610

University of Florida, Gainesville

37660

Holston Valley Hospital, Kingsport

43214

OhioHealth Research Institute, Columbus

43614

University of Toledo Medical Center, Toledo

60007

Alexian Brothers Medical Center, Elk Grove Village

94304

VA Palo Alto Health Care System, Palo Alto

94305

Stanford University Medical School, Stanford

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Cook Research Incorporated

INDUSTRY

NCT01901289 - Zilver® PTX® V Clinical Study | Biotech Hunter | Biotech Hunter